Engineered donor cells take aim at returning blood cancers after transplant

This early-phase study tests a new approach for people whose lymphoma or leukemia has returned after a donor stem cell transplant. Researchers take T cells from the original stem cell donor, add a special receptor (anti-CD19) to help them recognize and attack cancer cells, and infuse them into the patient. The goal is to find a safe dose and see if these engineered cells can control the cancer without causing severe side effects like graft-versus-host disease.